All terms

    Medhacking

    Umbrella term for hacking activity directed at medical devices, ranging from criminal attack to coordinated security research and patient-led modification.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed September 19, 2026

    Definition

    Medhacking is an informal umbrella term for hacking activity directed at medical devices and clinical systems. It covers three overlapping populations: (1) malicious actors attacking devices to harm patients, extort hospitals, or pivot into healthcare networks (overlapping with medjacking); (2) security researchers performing coordinated vulnerability disclosure under programs aligned with the FDA-recognized ISO/IEC 29147 and 30111 standards; and (3) patient and DIY communities modifying their own devices for clinical benefit - most visibly the #WeAreNotWaiting movement that built open-source automated insulin delivery systems (OpenAPS, Loop, AndroidAPS) on top of commercial insulin pumps and CGMs. The term is not a regulatory category; it is a shorthand the press, conference circuit (DEF CON Biohacking Village), and patient communities use to describe the broader phenomenon of technical intervention into medical devices outside the manufacturer's intended pathway.
    What the regulation says
    Regulators do not use 'medhacking' as a formal term, but they address its three branches separately. Malicious activity is handled through FDA safety communications, CISA medical-device advisories, and FBI/HHS cyber notifications. Coordinated security research is encouraged: FDA's 2023 cybersecurity guidance and the HSCC Medical Device and Health IT Joint Security Plan call for manufacturers to operate a coordinated vulnerability disclosure program aligned with ISO/IEC 29147 and 30111, and the DEF CON Biohacking Village Device Lab is run with explicit FDA participation. Patient self-modification (e.g., open-source AID) is unapproved use; FDA's 2019 safety communication on unauthorized AID systems sets the regulator's position.

    What this means in practice

    For manufacturers, the practical implication is to plan for all three populations: a hardened device, a published coordinated vulnerability disclosure policy and security.txt, an active relationship with the security research community (Biohacking Village, ICS-CERT, MDIC), and clear labeling and human-factors design that anticipate motivated patient modification - especially in chronic-disease devices like insulin pumps and CGMs.

    Examples

    • A malicious actor exploited a known vulnerability in an unpatched imaging system to gain unauthorized access to patient records, leading to a data breach and potential exposure of sensitive health information.
    • A team of independent security researchers responsibly disclosed a critical vulnerability in an infusion pump's network communication protocol to the manufacturer and relevant regulatory bodies, allowing for a patch to be developed before patient harm occurred.
    • Patients with a chronic condition collaboratively developed and shared an open-source software solution that allowed their off-the-shelf therapeutic devices to interoperate and provide more personalized, automated treatment management than commercially available options.
    Common pitfalls
    • •Treating all medhackers as adversaries and lacking a coordinated vulnerability disclosure channel.
    • •Threatening security researchers with legal action instead of triaging their findings - a known reputational disaster in MedTech.
    • •Ignoring patient-driven modification trends until they become a safety communication.
    • •Conflating medhacking, medjacking, and brainjacking in internal risk documentation - regulators expect precise language.

    Frequently asked questions

    It depends on which branch. Malicious attacks on devices are crimes under the Computer Fraud and Abuse Act and equivalents abroad. Coordinated security research under a published disclosure policy is legal and increasingly safe-harbored. Patients modifying their own devices occupy a gray zone - it is unapproved use under FDA's framework but is not, in itself, criminally prosecuted.
    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Latest in MedTech

    Sources

    6 sources

    Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

    Tier 1Binding law and standards· 2Tier 2Regulator guidance and consensus· 2Tier 4Trade press and expert commentary· 2
    Link health: 5 verified 1 unchecked· last checked 2026-06-20
    FDA·2ISO/IEC·2Biohacking Village·1HSCC·1
    1. 1
      FDA Cybersecurity Guidance (Sept 2023)
      Tier 2 Verified
      FDAfda.gov
    2. 2
      ISO/IEC 29147:2018 Vulnerability Disclosure
      Tier 1 Verified
      ISO/IECiso.org
    3. 3
      ISO/IEC 30111:2019 Vulnerability Handling Processes
      Tier 1 Verified
      ISO/IECiso.org
    4. 4
      DEF CON Biohacking Village Device Lab
      Tier 4 Verified
      Biohacking Villagevillageb.io
    5. 5
      FDA Safety Communication on Unauthorized Automated Insulin Dosing Systems (2019)
      Tier 2 Unchecked
      FDAfda.gov
    6. 6
      HSCC Medical Device and Health IT Joint Security Plan
      Tier 4 Verified
      HSCChealthsectorcouncil.org

    Inline markers like [1] jump to the matching reference above.